The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections

Epidemiology of Meropenem/Vaborbactam Resistance in KPC-Producing Klebsiella pneumoniae Causing Bloodstream Infections in Northern Italy, 2018

(2021) Paolo Gaibani et al.   Antibiotics-Basel

Potency of Vaborbactam is Less Affected than Avibactam in Strains Producing KPC-2 Mutations that Confer Resistance to Ceftazidime-Avibactam

(2020) Ruslan Tsivkovski et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Meropenem/Vaborbactam versus Ceftazidime/Avibactam for Treatment of Carbapenem-Resistant Enterobacteriaceae Infections

(2020) Renee Ackley et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Epidemiology of β-Lactamase-Producing Pathogens

(2020) Karen Bush et al.   CLINICAL MICROBIOLOGY REVIEWS

Real-world Multicenter Analysis of Clinical Outcomes and Safety of Meropenem-Vaborbactam in Patients Treated for Serious Gram-Negative Bacterial Infections

(2020) Sara Alosaimy et al.   Open Forum Infectious Diseases

Effects of KPC variant and porin genotype on the in vitro activity of meropenem-vaborbactam against carbapenem-resistant Enterobacteriaceae

(2019) William R. Wilson et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy of Human-Simulated Epithelial Lining Fluid Exposure of Meropenem-Nacubactam Combination against Class A Serine β-Lactamase-Producing Enterobacteriaceae in the Neutropenic Murine Lung Infection Model

(2019) Tomefa E. Asempa et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Efficacy and Safety of Meropenem–Vaborbactam Versus Best Available Therapy for the Treatment of Carbapenem-Resistant Enterobacteriaceae Infections in Patients Without Prior Antimicrobial Failure: A Post Hoc Analysis

(2019) Matteo Bassetti et al.   ADVANCES IN THERAPY

Nacubactam Enhances Meropenem Activity against Carbapenem-Resistant Klebsiella pneumoniae Producing KPC

(2019) Melissa D. Barnes et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals During 2016-2018

(2019) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Early experience with meropenem-vaborbactam for treatment of carbapenem-resistant Enterobacteriaceae infections

(2019) Ryan K Shields et al.   CLINICAL INFECTIOUS DISEASES

Monotherapy versus combination therapy for multidrug-resistant Gram-negative infections: Systematic Review and Meta-Analysis

(2019) Adrian Schmid et al.   Scientific Reports

Choice of therapeutic interventions and outcomes for the treatment of infections caused by multidrug-resistant gram-negative pathogens: a systematic review

(2019) Sarah Melissa Nørgaard et al.   Antimicrobial Resistance and Infection Control

In Vivo Efficacy of Meropenem, with a novel non-β-lactam β-lactamase Inhibitor, Nacubactam, against Gram-negative Organisms Exhibiting Various Resistance Mechanisms in a Murine Complicated Urinary Tract Infection Model

(2018) Marguerite L. Monogue et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Single-Dose Pharmacokinetics and Safety of Meropenem-Vaborbactam in Subjects with Chronic Renal Impairment

(2018) Christopher M. Rubino et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftazidime/avibactam, Meropenem/vaborbactam or both? Clinical and formulary considerations

(2018) Jason M Pogue et al.   CLINICAL INFECTIOUS DISEASES

Effect of Meropenem-Vaborbactam vs Piperacillin-Tazobactam on Clinical Cure or Improvement and Microbial Eradication in Complicated Urinary Tract Infection

(2018) Keith S. Kaye et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Treatment of infections caused by multidrug-resistant Gram-negative bacteria: report of the British Society for Antimicrobial Chemotherapy/Healthcare Infection Society/British Infection Association Joint Working Party†

(2018) Peter M Hawkey et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

β-lactam/β-lactamase inhibitor combinations: an update

(2018) Kamaleddin H. M. E. Tehrani et al.   MedChemComm

Pharmacokinetics/Pharmacodynamics of Vaborbactam, a Novel Beta-Lactamase Inhibitor, in Combination with Meropenem

(2018) David C. Griffith et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Meropenem-Vaborbactam as Salvage Therapy for Ceftazidime-Avibactam-Resistant Klebsiella pneumoniae Bacteremia and Abscess in a Liver Transplant Recipient

(2018) Vasilios Athans et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model

(2018) Mojgan Sabet et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of nacubactam (RG6080/OP0595) combinations against MBL-producing Enterobacteriaceae

(2018) Shazad Mushtaq et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of the β-Lactamase Inhibitor Vaborbactam (RPX7009) in Healthy Adult Subjects

(2016) David C. Griffith et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Effect of the β-Lactamase Inhibitor Vaborbactam Combined with Meropenem against Serine Carbapenemase-Producing Enterobacteriaceae

(2016) Mariana Castanheira et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Meropenem-RPX7009 Concentrations in Plasma, Epithelial Lining Fluid, and Alveolar Macrophages of Healthy Adult Subjects

(2015) Eric Wenzler et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases

(2013) L Silvia Munoz-Price et al.   LANCET INFECTIOUS DISEASES

Carbapenems: Past, Present, and Future

(2011) Krisztina M. Papp-Wallace et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY